End-of-day quote
Korea S.E.
06:00:00 2024-06-19 pm EDT
5-day change
1st Jan Change
180,100
KRW
-1.80%
-1.37%
-10.62%
Celltrion, Inc.'s Equity Buyback announced on November 9, 2023, has closed with 1,314,286 shares, representing 0.93% for KRW 216,584.47 million.
The company closed its plan on December 13, 2023.
Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug
Jun. 17
MT
Celltrion, Inc. announces an Equity Buyback for 410,734 shares.
Jun. 13
CI
Celltrion Showcases Promising Results in Phase III study for CT-P47, A Biosimilar Candidate of Roactemra® (Tocilizumab) in Patients with Rheumatoid Arthritis (RA) at EULAR 2024
Jun. 13
CI
Celltrion, Inc. authorizes a Buyback Plan.
Jun. 13
CI
Celltrion's Avastin Biosimilar Gains 12% Market Share in Japan
Jun. 07
MT
AbbVie's tight grip on Humira market raises concerns about biosimilars
Jun. 07
RE
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 17, 2024.
Jun. 04
CI
Celltrion, Inc.'s Equity Buyback announced on April 17, 2024, has closed with 436,047 shares, representing 0.21% for KRW 80,550.32 million.
May. 30
CI
Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe
May. 23
CI
Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 16
CI
Celltrion's Q1 Attributable Profit Slumps 86%
May. 10
MT
Market Share of Celltrion’s Remsima Rises to 74% in Europe
Apr. 24
MT
Celltrion, Inc. announces an Equity Buyback for 436,047 shares.
Apr. 17
CI
Celltrion, Inc. authorizes a Buyback Plan.
Apr. 16
CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on March 5, 2024.
Mar. 28
CI
Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million.
Mar. 25
CI
Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 18
CI
South Korean Shares Close Higher on Tech Gains; Celltrion Shares Add 1% on Zymfentra Launch in the US
Mar. 18
MT
Celltrion's Autoimmune Disease Treatment Hits US Markets
Mar. 18
MT
South Korean Shares Slightly Slip as Investors Seek Cues on Future Rate Direction from US Fed
Mar. 06
MT
Celltrion Announces 75 Billion Won Share Buyback Plan
Mar. 06
MT
Celltrion, Inc. announces an Equity Buyback for 425,895 shares.
Mar. 04
CI
Celltrion, Inc. authorizes a Buyback Plan.
Mar. 04
CI
South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings
Feb. 29
MT
Celltrion's Net Profit Nosedives 98.5% in Q4 2023 as Revenue Declines 25%
Feb. 29
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
More about the company
Last Close Price
180,100
KRW
Average target price
231,375
KRW
Spread / Average Target
+28.47%
Consensus
1st Jan change
Capi.
-10.62% 26.68B +35.14% 51.51B -7.43% 39.03B +34.35% 38.91B +11.63% 26.13B -17.77% 19.91B +40.52% 13.71B +30.70% 12.38B -3.41% 11.74B -11.32% 10.8B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1